Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Ä¡·á¿¡ ¹ÝÀÀÇÏÁö ¾ÊÀº ¼ºÀÎ ¿ëÇ÷¼º ¿äµ¶ ÁõÈıº ȯÀÚ¿¡¼­ Cryosupernatant¸¦ »ç¿ëÇÑ Ç÷Àå ±³È¯ Ä¡·á Plasma Exchange with Cryosnpernatant in the Patient with Refractory Hemolytic Uremic Syndrome

´ëÇѽÅÀåÇÐȸÁö 1997³â 16±Ç 4È£ p.768 ~ 773
¼Ò¼Ó »ó¼¼Á¤º¸
À̱Թé/Kyu Beck Lee ±èÀ±±¸/ÀÌÀ±ÇÏ/±è´ëÁß/¿ÀÇÏ¿µ/±è´ë¿ø/³²ÀÌÇö/À弼ȣ/À弼ȣ/Yoon Goo Kim/Yoon Ha Lee/Dea Joong Kim/Ha Young Oh/Dea Won Kim/Yee Hyun Nam/Seo Ho Jang/Seo Ho Jang

Abstract

¼­·Ð
¿ëÇ÷¼º ¿äµ¶ ÁõÈıºÀº ¹Ì¼¼Ç÷°ü¼º ¿ëÇ÷¼º ºóÇ÷, Ç÷¼ÒÆÇ °¨¼ÒÁõ°ú ½ÅºÎÀüÀÌ Æ¯Â¡ÀûÀÎ Áúȯ
ÀÌ´Ù ¹ßº´±âÀüÀº Ç÷Àü¼º Ç÷¼ÒÆÇ °¨¼Ò¼º ÀÚ¹ÝÁõ°ú µ¿ÀÏÇÑ ¹Ì¼¼Ç÷°üÀÇ Ç÷Àü¼º º´º¯À̸ç, µÎ
ÁúȯÀÌ ÀÓ»ó»óÀ¸·Î ±¸ºÐÀÌ ¾î·Á¿î °æ¿ì°¡ ÀÖ¾î ¿ëÇ÷¼º ¿äµ¶ ÁõÈıº-Ç÷Àü¼º Ç÷¼ÒÆÇ°¨¼Ò¼º
ÀÚ¹ÝÁõÀ¸·Î ºÒ¸® ¿ì±âµµ ÇÑ´Ù. °ú°Å¿¡´Â Ä¡¸íÀûÀ̾ú´ø Ç÷Àü¼º Ç÷¼ÒÆÇ °¨¼Ò¼º ÀÚ¹ÝÁõÀº Ç÷Àå
Ä¡·áµµÀÔ ÈÄ ¿¹ÈÄ¿¡ ÇöÀúÇÑ °³¼±ÀÌ ÀÖ¾ú´Ù. ±×·¯³ª Ç÷Àå Ä¡·á¿¡µµ ºÒ±¸ÇÏ°í ÀϺΠȯÀÚ¿¡¼­
Àü°Ý¼ºÀ¸·Î ÁøÇàÇÏ¿© »ç¸ÁÇÏ´Â ¿¹°¡ ÀÖÀ¸¸ç, Ãʱ⠹ÝÀÀ ÈÄ¿¡µµ Àç¹ßÇÏ´Â ¿¹°¡ ÀÖ¾î ¹®Á¦°¡
µÇ°í ÀÖ´Ù. ÀÌ·¯ÇÑ È¯ÀÚ´Â Ç÷°ü³»ÇǼ¼Æ÷¿¡¼­ À¯·¡µÈ ´Ù·®ÀÇ unusually large von Willebrand
factor multimer(ÀÌÇÏ ULvWFM)°¡ Ç÷¼ÒÆÇ ÀÀÁýÀÇ ÁÖ¿øÀÎÀ¸·Î ÀÛ¿ëÇÑ´Ù. ±×¸®°í Ç÷Àå ±³È¯
Ä¡·áÀÇ º¸Ãæ¾×ÀÎ ½Å¼± µ¿°á Ç÷Àå¿¡ Æ÷ÇÔµÈ ULVWFMµµ Ç÷¼ÒÆÇ ÀÀÁýÀ» ÀÏÀ¸Å²´Ù.
Cryosupernatant´Â ½Å¼± µ¿°á Ç÷ÀåÀ» ¿ø½ÉºÐ¸®ÇÏ¿© ULvWFN°¡ Æ÷ÇÔµÈ µ¿°á ħÀü¹°À» Á¦°Å
ÇÑ »óû¾×À» ¸»Çϸç, ½Å¼± µ¿°á Ç÷ÀåÀ» »ç¿ëÇÑ Ç÷Àå ±³È¯ Ä¡·á¿¡ ¹ÝÀÀÀÌ ¾ø´Â ȯÀÚ¿¡¼­
cryosupernatant¸¦ º¸Ãæ¾×À¸·Î »ç¿ëÇϸé Ä¡·á¿¡ ÁÁÀº ¹Ý¿õÀ» º¸ÀÌ´Â °ÍÀ¸·Î º¸°íµÇ°í ÀÖ´Ù.
µû¶ó¼­ Ä¡·á¿¡ ¹ÝÀÀÇÏÁö ¾ÊÀº ¼ºÀÎ ¿ëÇ÷¼º ¿äµ¶ ÁõÈıº¿¡¼­µµ cryosupernatant·Î Ç÷Àå ±³È¯
Ä¡·á¸¦ ½ÃÇàÇϸé Ä¡·á¿¡ ÁÁÀº ¹ÝÀÀÀÌ ÀÖÀ» °ÍÀ¸·Î »ý°¢ÇÏ¿´´Ù.
ÀúÀÚµéÀº ½Å¼± µ¿°á Ç÷ÀåÀ¸·Î Ç÷Àå ±³È¯ Ä¡·á¸¦ ½ÃÇàÇÏ¿´À¸³ª ¹ÝÀÀÇÏÁö ¾ÊÀº ¼ºÀÎ ¿ëÇ÷¼º
¿äµ¶ ÁõÈıº ȯÀÚ¿¡¼­ cryosupernatant¸¦ »ç¿ëÇÑ Ç÷Àå ±³È¯ Ä¡·á¸¦ ½ÃÇàÇÏ¿© ÁÁÀº Ãâ°ú¸¦
¾òÀº 1¿¹¸¦ º¸°íÇÏ´Â ¹ÙÀÌ´Ù.
#ÃÊ·Ï#
Many patients with Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic
Syndrome(TTP-HUS) satisfactorily respond to plasma exchange. Some patients,
however, respond either not at all or only transiently and incompletely. In the refractory
case, endothelial cell-derived unusually large von Willebrand factor multimers(ULvWFM)
have an important role in the formation of microthrombi. As the ULvWFM may be
removed in the cryoprecipitate, we reason the plasma depleted of cryoprecipitate(the
plasma cryosupematant) should be considered for effectiveness in the treatment of
refractory TTP-HUS.
We experienced a 48 year old woman presented with diarrhea, jaundice and oliguria.
She had microangiopathic hemolytic anemia, renal impairment, platelets of
21,000/mm3 and LDH 3,258U/L. She had not improved after plasma
exchange with fresh frozen plasma(FFP)(1.5 plasma volume¡¿7 days). On hospital day 8,
her HUS had not responded, platelets of 37,000/3 and LDH 1,588U/L.
Substitution of cryosupernatant for FFP was associated with prompt increased in the
platelet count to normal and complete resolution of HUS. Therefore. the cryosupernatant
fraction of plasma should be considered as an alternative to whole FFP for plasma
exchange if there is continuing platelet consumption and micro-vascular thrombosis in
spite of intensive conventional plasma therapy.

Å°¿öµå

Cryosupematant; Hemolytic uremic syndrome; Unusually large von Willebrand factor multimers;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS